California Public Employees Retirement System trimmed its holdings in Natera, Inc. (NASDAQ:NTRA – Get Rating) by 5.1% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 153,703 shares of the medical research company’s stock after selling 8,188 shares during the quarter. California Public Employees Retirement System’s holdings in Natera were worth $5,447,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Parallel Advisors LLC raised its stake in shares of Natera by 84.2% in the second quarter. Parallel Advisors LLC now owns 829 shares of the medical research company’s stock worth $29,000 after acquiring an additional 379 shares during the last quarter. Assetmark Inc. increased its holdings in shares of Natera by 93.6% in the second quarter. Assetmark Inc. now owns 873 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 422 shares in the last quarter. San Luis Wealth Advisors LLC acquired a new position in Natera during the 1st quarter worth $34,000. Allworth Financial LP lifted its holdings in Natera by 49,000.0% during the 2nd quarter. Allworth Financial LP now owns 1,473 shares of the medical research company’s stock worth $52,000 after buying an additional 1,470 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its position in Natera by 215.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,049 shares of the medical research company’s stock valued at $83,000 after buying an additional 1,399 shares during the last quarter. Institutional investors and hedge funds own 92.95% of the company’s stock.
Insiders Place Their Bets
In other news, CEO Steven Leonard Chapman sold 1,674 shares of the firm’s stock in a transaction dated Friday, September 23rd. The stock was sold at an average price of $45.30, for a total transaction of $75,832.20. Following the sale, the chief executive officer now owns 68,313 shares of the company’s stock, valued at $3,094,578.90. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CEO Steven Leonard Chapman sold 1,674 shares of the company’s stock in a transaction that occurred on Friday, September 23rd. The shares were sold at an average price of $45.30, for a total value of $75,832.20. Following the completion of the transaction, the chief executive officer now owns 68,313 shares in the company, valued at $3,094,578.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Michael Burkes Brophy sold 915 shares of the business’s stock in a transaction on Wednesday, September 28th. The shares were sold at an average price of $44.04, for a total transaction of $40,296.60. Following the completion of the sale, the chief financial officer now directly owns 85,669 shares in the company, valued at $3,772,862.76. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 18,359 shares of company stock worth $797,832. Corporate insiders own 10.27% of the company’s stock.
Analyst Ratings Changes
Natera Price Performance
Shares of NTRA stock opened at $37.23 on Friday. The company has a quick ratio of 2.95, a current ratio of 3.10 and a debt-to-equity ratio of 0.78. Natera, Inc. has a 12-month low of $26.10 and a 12-month high of $99.63. The firm has a fifty day moving average of $42.74 and a 200-day moving average of $42.79. The firm has a market capitalization of $3.63 billion, a price-to-earnings ratio of -6.55 and a beta of 1.33.
Natera Company Profile
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
- Get a free copy of the StockNews.com research report on Natera (NTRA)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.